Related Experiment Video
Updated: Feb 25, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus
Michele Massimo Gulizia1,2, Furio Colivicchi1, Gualtiero Ricciardi3
1Italian Association of Hospital Cardiologists (ANMCO).
Insights
This guideline details managing high cholesterol (hypercholesterolemia) to prevent atherosclerotic cardiovascular disease, the leading cause of death. It covers risk assessment and therapeutic options for cholesterol reduction.
Area of Science:
- Cardiology
- Public Health
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a primary cause of mortality in Western nations.
- Elevated blood cholesterol is a significant factor in the development and advancement of atherosclerotic plaques.
- Pharmacological interventions like statins and ezetimibe effectively reduce cholesterol and improve clinical outcomes.
Purpose of the Study:
- To provide comprehensive clinical management guidelines for hypercholesterolemia.
- To detail the role of hypercholesterolemia in ASCVD pathogenesis.
- To explore therapeutic strategies for cholesterol reduction and cardiovascular risk mitigation.
Main Methods:
- Consensus document developed by 16 Italian medical associations and the Italian National Institute of Health.
- Detailed analysis of hypercholesterolemia's impact on cardiovascular risk profiles.
- Exploration of all available diagnostic and therapeutic pathways for hypercholesterolemia management.
Main Results:
- High cholesterol levels are intrinsically linked to the genesis of atherosclerotic cardiovascular disease.
- Individual cardiovascular risk assessment must incorporate cholesterol levels.
- Various therapeutic options exist for effective blood cholesterol reduction.
Conclusions:
- This document outlines diagnostic and therapeutic strategies for managing patients with hypercholesterolemia.
- Effective management of hypercholesterolemia is crucial for mitigating cardiovascular risk.
- Adherence to established guidelines can improve clinical outcomes in patients with high cholesterol.
Abstract:
Atherosclerotic cardiovascular disease still represents the leading cause of death in Western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proved effective in improving clinical outcomes. This document focuses on the clinical management of hypercholesterolaemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors discuss in detail the role of hypercholesterolaemia in the genesis of atherosclerotic cardiovascular disease. In addition, the implications for high cholesterol levels in the definition of the individual cardiovascular risk profile have been carefully analysed, while all available therapeutic options for blood cholesterol reduction and cardiovascular risk mitigation have been explored. Finally, this document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolaemia.
